Therefore, in this era of precision medicine, we conclude that combination therapy involving pathway-selective kinase inhibitors and PRLR inhibitors depending on the status of the breast cancer can provide better outcomes in clinical studies. This evidence concerns the gene PRLR and breast cancer.